Search

Your search keyword '"carob bean gum"' showing total 5 results
Start Over Descriptor "carob bean gum" Topic regurgitation
5 results on '"carob bean gum"'

1. Locust bean gum safety in neonates and young infants: An integrated review of the toxicological database and clinical evidence.

Author

Meunier, Leo, Garthoff, Jossie A., Schaafsma, Anne, Krul, Lisette, Schrijver, Jaap, van Goudoever, Johannes B., Speijers, Gerrit, and Vandenplas, Yvan

Subjects
*LOCUST bean gum, *NEWBORN infants, *GALACTOMANNANS, *GASTROESOPHAGEAL reflux, *PEDIATRICS, *DRUG administration
Abstract

Locust bean gum (LBG) is a galactomannan polysaccharide used as thickener in infant formulas with the therapeutic aim to treat uncomplicated gastroesophageal reflux (GER). Since its use in young infants below 12 weeks of age is not explicitly covered by the current scientific concept of the derivation of health based guidance values, the present integrated safety review aimed to compile all the relevant preclinical toxicological studies and to combine them with substantial evidence gathered from the clinical paediatric use as part of the weight of evidence supporting the safety in young infants below 12 weeks of age. LBG was demonstrated to have very low toxicity in preclinical studies mainly resulting from its indigestible nature leading to negligible systemic bioavailability and only possibly influencing tolerance. A standard therapeutic level of 0.5 g/100 mL in thickened infant formula is shown to confer a sufficiently protective Margin of Safety. LBG was not associated with any adverse toxic or nutritional effects in healthy term infants, while there are limited case-reports of possible adverse effects in preterms receiving the thickener inappropriately. Altogether, it can be concluded that LBG is safe for its intended therapeutic use in term-born infants to treat uncomplicated regurgitation from birth onwards. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

2. Effect of carob bean on gastric emptying time in Thai infants.

Author

Vivatvakin, Boosba and Buachum, Vacharee

Subjects
*BODY weight, *GASTROESOPHAGEAL reflux, *INFANT nutrition, *INFANT formulas, *ABDOMINAL pain, *HEARTBURN
Abstract

Thickening agents, such as carob bean gum or galactomannan, have been successfully administered for the treatment of gastro esophageal reflux in infants. To study the effect of carob bean gum on gastric emptying and to symptoms of regurgitation, we recruited 20 full term Thai infants (mean age 13.4 ± 7 week; mean body weight = 4943 ± 1272gm) without pathological gastroesophageal reflux. Initially, we determined halftime gastric emptying (T 1/2 GET) by Tc99m radioscintigraphy method (mean T 1/2 GET = 116.1 ±72 mm) in infants consuming standard infant cow's milk formula for 2 weeks. Afterwards, carob bean infant formula was given for 2-4 weeks and weight gain, vomiting symptoms, night cough, colic, flatus, defaecation character and T 1/2 GET were assessed. There were statistically significant improvements in symptoms of vomiting (a smaller quantity P<0.00l and frequency of vomiting P < 0.0001) and improvements in weight gain per week (W1 = 121.2 + 106.9gm, W2 221.3 + 136.1gm; P = 0.005) when infants consumed the carob bean formula. However, there was no significance difference in gastric emptying half time (GET1 = 116.1 + 72, GET2 = 148.5 + 130.9; P= 0.154). In conclusion, carob bean gum, as a thickening agent, improves the clinical symptoms of regurgitating infants, but does not significantly alter the gastric emptying physiology. [ABSTRACT FROM AUTHOR]

Published
2003

3. Locust bean gum safety in neonates and young infants: An integrated review of the toxicological database and clinical evidence

Author

Anne Schaafsma, Johannes B. van Goudoever, Jossie A. Garthoff, Lisette Krul, Jaap Schrijver, Yvan Vandenplas, Leo Meunier, Gerrit J.A. Speijers, Pediatric surgery, and ICaR - Circulation and metabolism

Subjects
Pediatrics, Reproductive toxicity, Databases, Factual, Unclassified drug, Locust beam gum, Locust bean gum, Biomedical Innovation, RAPID - Risk Assessment Products in Development, Toxicology, Artificial milk, Galactans, Mannans, chemistry.chemical_compound, In vivo study, Teratogenicity, Chemical structure, Life, Plant Gums, Polysaccharide, Chronic toxicity, Priority journal, Carcinogenicity, Surface property, General Medicine, Regurgitation, Nutritional assessment, Carob bean gum, Health, Gastroesophageal Reflux, Infant formula, Food composition, Safety, Thickness, Infants, Healthy Living, Human, medicine.medical_specialty, Biological Availability, Food safety, Galactomannan, medicine, Hypersensitivity, Humans, Adverse effect, Food additive, Acute toxicity, business.industry, Dietary intake, Infant, Newborn, Infant, In vitro study, medicine.disease, Nonhuman, Surgery, chemistry, GERD, Toxicity testing, Thickener, ELSS - Earth, Life and Social Sciences, Genotoxicity, business, Gastro-oesophageal reflux
Abstract

Locust bean gum (LBG) is a galactomannan polysaccharide used as thickener in infant formulas with the therapeutic aim to treat uncomplicated gastroesophageal reflux (GER). Since its use in young infants below 12. weeks of age is not explicitly covered by the current scientific concept of the derivation of health based guidance values, the present integrated safety review aimed to compile all the relevant preclinical toxicological studies and to combine them with substantial evidence gathered from the clinical paediatric use as part of the weight of evidence supporting the safety in young infants below 12. weeks of age. LBG was demonstrated to have very low toxicity in preclinical studies mainly resulting from its indigestible nature leading to negligible systemic bioavailability and only possibly influencing tolerance. A standard therapeutic level of 0.5. g/100. mL in thickened infant formula is shown to confer a sufficiently protective Margin of Safety. LBG was not associated with any adverse toxic or nutritional effects in healthy term infants, while there are limited case-reports of possible adverse effects in preterms receiving the thickener inappropriately. Altogether, it can be concluded that LBG is safe for its intended therapeutic use in term-born infants to treat uncomplicated regurgitation from birth onwards. © 2014 The Authors. Chemicals/CAS: galactomannan, 11078-30-1

Published
2014
Full Text
View/download PDF

4. Locust bean gum safety in neonates and young infants : an integrated review of the toxicological database and clinical evidence

Author

Meunier, L., Garthoff, J., Schaafsma, A., Krul, L., De Schrijver, J., Goudoever, J., Vandenplas, Yvan, and Growth and Development

Subjects
safety, Carob bean gum, Locust bean gum, gastro-oesophageal reflux, infant formula, Thickener, REGURGITATION
Abstract

Locust bean gum (LBG) is a galactomannan polysaccharide used as thickener in infant formulas with the therapeutic aim to treat uncomplicated gastroesophageal reflux (GER). Since its use in young infants below 12 weeks of age is not explicitly covered by the current scientific concept of the derivation of health based guidance values, the present integrated safety review aimed to compile all the relevant preclinical toxicological studies and to combine them with substantial evidence gathered from the clinical paediatric use as part of the weight of evidence supporting the safety in young infants below 12 weeks of age. LBG was demonstrated to have very low toxicity in preclinical studies mainly resulting from its indigestible nature leading to negligible systemic bioavailability and only possibly influencing tolerance. A standard therapeutic level of 0.5 g/100 mL in thickened infant formula is shown to confer a sufficiently protective Margin of Safety. LBG was not associated with any adverse toxic or nutritional effects in healthy term infants, while there are limited case-reports of possible adverse effects in preterms receiving the thickener inappropriately. Altogether, it can be concluded that LBG is safe for its intended therapeutic use in term-born infants to treat uncomplicated regurgitation from birth onwards.

Published
2014

5. Locust bean gum safety in neonates and young infants: An integrated review of the toxicological database and clinical evidence

Subjects
Reproductive toxicity, Unclassified drug, Locust beam gum, Locust bean gum, Biomedical Innovation, RAPID - Risk Assessment Products in Development, Artificial milk, Food safety, In vivo study, Chronic toxicity, Teratogenicity, Chemical structure, Life, Hypersensitivity, Life and Social Sciences, Polysaccharide, Priority journal, Food additive, Acute toxicity, Carcinogenicity, Dietary intake, Surface property, In vitro study, Regurgitation, ELSS - Earth, Nonhuman, Nutritional assessment, Carob bean gum, Health, Galactomannan, Infant formula, Toxicity testing, Thickener, Food composition, Genotoxicity, Safety, Thickness, Infants, Healthy Living, Gastro-oesophageal reflux, Human
Abstract

Locust bean gum (LBG) is a galactomannan polysaccharide used as thickener in infant formulas with the therapeutic aim to treat uncomplicated gastroesophageal reflux (GER). Since its use in young infants below 12. weeks of age is not explicitly covered by the current scientific concept of the derivation of health based guidance values, the present integrated safety review aimed to compile all the relevant preclinical toxicological studies and to combine them with substantial evidence gathered from the clinical paediatric use as part of the weight of evidence supporting the safety in young infants below 12. weeks of age. LBG was demonstrated to have very low toxicity in preclinical studies mainly resulting from its indigestible nature leading to negligible systemic bioavailability and only possibly influencing tolerance. A standard therapeutic level of 0.5. g/100. mL in thickened infant formula is shown to confer a sufficiently protective Margin of Safety. LBG was not associated with any adverse toxic or nutritional effects in healthy term infants, while there are limited case-reports of possible adverse effects in preterms receiving the thickener inappropriately. Altogether, it can be concluded that LBG is safe for its intended therapeutic use in term-born infants to treat uncomplicated regurgitation from birth onwards. © 2014 The Authors. Chemicals/CAS: galactomannan, 11078-30-1

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results